Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate.
Marco CavalliNiclas ErikssonJohanna Karlsson SundbaumMatilda WallenbergHugo KohnkeEva BaecklundPär HallbergMia WadeliusPublished in: Pharmacogenomics (2022)
Aim: A follow-up genome-wide association study (GWAS) in an extended cohort of rheumatoid arthritis (RA) patients starting low-dose methotrexate (MTX) treatment was performed to identify further genetic variants associated with alanine aminotransferase (ALT) elevation. Patients & methods: A GWAS was performed on 346 RA patients. Two outcomes within the first 6 months of MTX treatment were assessed: ALT >1.5-times the upper level of normal (ULN) and maximum level of ALT. Results: SPATA9 (rs72783407) was significantly associated with maximum level of ALT (p = 2.58 × 10 -8 ) and PLCG2 (rs60427389) was tentatively associated with ALT >1.5 × ULN. Conclusion: Associations with SNPs in genes related to male fertility ( SPATA9 ) and inflammatory processes ( PLCG2 ) were identified.
Keyphrases
- low dose
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- high dose
- disease activity
- peritoneal dialysis
- rheumatoid arthritis patients
- gene expression
- adipose tissue
- patient reported outcomes
- weight loss
- insulin resistance
- smoking cessation
- patient reported
- childhood cancer